Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR1 | P30556 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | ACP1 | P24666 | 2/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | ACHE | P22303 | 2/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | KDM1A | O60341 | 2/20 | 0.30 |
| ▸ | KDM1B | Q8NB78 | 1/20 | 0.30 |
| ▸ | RAPGEF4 | Q8WZA2 | 2/20 | 0.30 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.30 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.30 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.30 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4602927 | 0.86 | AGTR1 (0.40) | AGTR1GAAALDH1A1SMN1; SMN2MAPT | |
| SCHEMBL13550027 | 0.86 | GAA (0.36) | AGTR1GAAALDH1A1SMN1; SMN2MAPT | |
| SCHEMBL22690036 | 0.82 | ACHE (0.40) | AGTR1GAAALDH1A1SMN1; SMN2MAPT | |
| SCHEMBL1088034 | 0.82 | CYP3A4 (0.35) | AGTR1TSHRGAAALDH1A1MAPT | |
| SCHEMBL30018244 | 0.82 | AGTR1 (0.32) | AGTR1GAA | |
| SCHEMBL31648971 | 0.82 | ACHE (0.40) | AGTR1GAAALDH1A1SMN1; SMN2MAPT | |
| SCHEMBL17466062 | 0.82 | AGTR1 (0.32) | AGTR1GAA | |
| SCHEMBL29560549 | 0.78 | NOTUM (0.36) | AGTR1SMN1; SMN2MAPTKMT2AHTT | |
| SCHEMBL22866837 | 0.78 | NOTUM (0.36) | AGTR1SMN1; SMN2MAPTKMT2AHTT | |
| SCHEMBL25839065 | 0.78 | GABRA1 (0.35) | AGTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260015350-A1 | AZAQUINAZOLINE PAN-KRAS INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2026-01-15 | — | — | US | disclosed |
| US-12466803-B2 | BCKDK inhibitors and/or degraders | PFIZER INC. (US) | 2025-11-11 | — | — | US | disclosed |
| WO-2025106910-A1 | DEGRADER MOLECULES TARGETING ANDROGEN RECEPTOR | FLARE THERAPEUTICS INC. (US) | 2025-05-22 | — | — | WO | disclosed |
| EP-4540255-A1 | AZAQUINAZOLINE PAN-KRAS INHIBITORS | Mirati Therapeutics, Inc. (US) | 2025-04-23 | — | — | EP | disclosed |
| WO-2025078808-A1 | NOVEL COMPOUNDS | SITRYX THERAPEUTICS LIMITED (GB) | 2025-04-17 | — | — | WO | disclosed |
| US-20250122212-A1 | NOVEL COMPOUNDS | SITRYX THERAPEUTICS LIMITED (GB) | 2025-04-17 | — | — | US | disclosed |
| CN-118451066-A | 3-Phenyl-1-benzothiophene-2-carboxylic acid derivatives as inhibitors of branched alpha ketoacid dehydrogenase kinase for the treatment of diabetes, kidney disease, NASH and heart failure | 辉瑞大药厂 | 2024-08-06 | — | — | CN | disclosed |
| WO-2023244615-A1 | AZAQUINAZOLINE PAN-KRAS INHIBITORS | Mirati Therapeutics, Inc. (US) | 2023-12-21 | — | — | WO | disclosed |
| CN-117024354-B | Preparation method of Rui Mi Buti Ni | 天津凯莱英制药有限公司 | 2023-12-08 | — | — | CN | disclosed |
| US-20230382900-A1 | INHIBITORS OF BTK | NEWAVE PHARMACEUTICAL INC. | 2023-11-30 | — | — | US | disclosed |
| CN-117024354-A | Preparation method of Rui Mi Buti Ni | 天津凯莱英制药有限公司 | 2023-11-10 | — | — | CN | disclosed |
| US-20230167080-A1 | BCKDK INHIBITORS AND/OR DEGRADERS | PFIZER INC. (US) | 2023-06-01 | — | — | US | disclosed |
| WO-2022094172-A2 | INHIBITORS OF BTK | NEWAVE PHARMACEUTICAL INC. (US) | 2022-05-05 | — | — | WO | disclosed |
| EP-3042903-B1 | Substituted hetero-bicyclic compounds, compositions and medicinal applications thereof | IMPETIS BIOSCIENCES LTD (IN) | 2019-08-14 | — | — | EP | disclosed |
| WO-2018035080-A1 | 2-OXO-IMIDAZOPYRIDINES AS REVERSIBLE BTK INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2018-02-22 | — | — | WO | disclosed |
| WO-2003034989-A2 | α-HYDROXYARYLBUTANAMINE INHIBITORS OF ASPARTYL PROTEASE | ENANTA PHARMACEUTICALS, INC. (US) | 2003-05-01 | — | — | WO | disclosed |
| EP-0045423-B1 | PROCESS FOR THE ALPHA-HALOGENATION OF POSSIBLY SUBSTITUTED METHYL AROMATICS | BAYER AG (DE) | 1984-02-22 | — | — | EP | disclosed |
| US-4351974-A | Preparation of 3-bromo-4-fluorotoluene | BAYER AKTIENGESELLSCHAFT (DE) | 1982-09-28 | — | — | US | disclosed |
| EP-0045423-A1 | Process for the alpha-halogenation of possibly substituted methyl aromatics | BAYER AG (DE) | 1982-02-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12466803-B2 | BCKDK inhibitors and/or degraders | BCKDK, KHK, PDK4 | AGTR1 676/4885TSHR 3463/4885GAA 154/4885 |
| US-20230167080-A1 | BCKDK INHIBITORS AND/OR DEGRADERS | BCKDK, KHK, PDK4 | AGTR1 676/4885TSHR 3463/4885GAA 154/4885 |
| US-20230382900-A1 | INHIBITORS OF BTK | BTK, SYK, LYN | AGTR1 3464/4885TSHR 1986/4885GAA 3094/4885 |
| US-20250122212-A1 | NOVEL COMPOUNDS | CYP11B1, CYP11B2, UGT1A1 | AGTR1 967/4885TSHR 4462/4885GAA 1251/4885 |
| US-20260015350-A1 | AZAQUINAZOLINE PAN-KRAS INHIBITORS | KRAS, NRAS, HRAS | AGTR1 346/4885TSHR 1916/4885GAA 4638/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.